136 related articles for article (PubMed ID: 35383004)
1. Identification and Validation of the Prognostic Impact of Metastatic Prostate Cancer Phenotypes.
Labe SA; Wang X; Lehrer EJ; Kishan AU; Spratt DE; Lin C; Morgans AK; Ponsky L; Garcia JA; Garrett S; Wang M; Zaorsky NG
Clin Genitourin Cancer; 2022 Aug; 20(4):371-380. PubMed ID: 35383004
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of a SEER-based prognostic nomogram for patients with bone metastatic prostate cancer.
Hou G; Zheng Y; Wei D; Li X; Wang F; Tian J; Zhang G; Yan F; Zhu Z; Meng P; Yuan J; Gao M; Li Z; Zhang B; Xing Z; Yuan J
Medicine (Baltimore); 2019 Sep; 98(39):e17197. PubMed ID: 31574827
[TBL] [Abstract][Full Text] [Related]
3. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis.
Armstrong AJ; Garrett-Mayer ES; Yang YC; de Wit R; Tannock IF; Eisenberger M
Clin Cancer Res; 2007 Nov; 13(21):6396-403. PubMed ID: 17975152
[TBL] [Abstract][Full Text] [Related]
4. Prognostic importance of concomitant non-regional lymph node and bone metastases in men with newly diagnosed metastatic prostate cancer.
Heesterman BL; van der Poel HG; Schoots IG; Mehra N; Aben KKH
BJU Int; 2022 Aug; 130(2):217-225. PubMed ID: 34741789
[TBL] [Abstract][Full Text] [Related]
5. Importance of non-regional lymph nodes in assigning risk in primary metastatic prostate cancer.
Ali A; Hoyle A; Mistry H; Clarke NW
BJU Int; 2019 Jan; 123(1):65-73. PubMed ID: 29777564
[TBL] [Abstract][Full Text] [Related]
6. Pan-cancer analysis of prognostic metastatic phenotypes.
Zaorsky NG; Wang X; Garrett SM; Lehrer EJ; Lin C; DeGraff DJ; Spratt DE; Trifiletti DM; Kishan AU; Showalter TN; Park HS; Yang JT; Chinchilli VM; Wang M
Int J Cancer; 2022 Jan; 150(1):132-141. PubMed ID: 34287840
[TBL] [Abstract][Full Text] [Related]
7. Improving Clinical Risk Stratification at Diagnosis in Primary Prostate Cancer: A Prognostic Modelling Study.
Gnanapragasam VJ; Lophatananon A; Wright KA; Muir KR; Gavin A; Greenberg DC
PLoS Med; 2016 Aug; 13(8):e1002063. PubMed ID: 27483464
[TBL] [Abstract][Full Text] [Related]
8. A nomogram model based on the number of examined lymph nodes-related signature to predict prognosis and guide clinical therapy in gastric cancer.
Li H; Lin D; Yu Z; Li H; Zhao S; Hainisayimu T; Liu L; Wang K
Front Immunol; 2022; 13():947802. PubMed ID: 36405735
[TBL] [Abstract][Full Text] [Related]
9. Survival analysis and development of a prognostic nomogram for bone-metastatic prostate cancer patients: A single-center experience in Indonesia.
Afriansyah A; Hamid ARA; Mochtar CA; Umbas R
Int J Urol; 2019 Jan; 26(1):83-89. PubMed ID: 30269369
[TBL] [Abstract][Full Text] [Related]
10. The prognosis of different distant metastases pattern in prostate cancer: A population based retrospective study.
Shou J; Zhang Q; Wang S; Zhang D
Prostate; 2018 May; 78(7):491-497. PubMed ID: 29436722
[TBL] [Abstract][Full Text] [Related]
11. Impact of the Site of Metastases on Survival in Patients with Metastatic Prostate Cancer.
Gandaglia G; Karakiewicz PI; Briganti A; Passoni NM; Schiffmann J; Trudeau V; Graefen M; Montorsi F; Sun M
Eur Urol; 2015 Aug; 68(2):325-34. PubMed ID: 25108577
[TBL] [Abstract][Full Text] [Related]
12. Construction and validation of web-based nomograms for detecting and prognosticating in prostate adenocarcinoma with bone metastasis.
Dong Q; Wu X; Gan W; Mok TN; Shen J; Zha Z; Chen J
Sci Rep; 2022 Nov; 12(1):18623. PubMed ID: 36329203
[TBL] [Abstract][Full Text] [Related]
13. Nomograms for predicting survival in patients with metastatic gastric adenocarcinoma who undergo palliative gastrectomy.
Ma T; Wu ZJ; Xu H; Wu CH; Xu J; Peng WR; Fan LL; Sun GP
BMC Cancer; 2019 Aug; 19(1):852. PubMed ID: 31462229
[TBL] [Abstract][Full Text] [Related]
14. Development and validation of prognostic nomograms for patients with metastatic prostate cancer.
Jiang WD; Yuan PC
Int Urol Nephrol; 2019 Oct; 51(10):1743-1753. PubMed ID: 31289983
[TBL] [Abstract][Full Text] [Related]
15. Predictors of skeletal-related events and mortality in men with metastatic, castration-resistant prostate cancer: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
Tablazon IL; Howard LE; De Hoedt AM; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Terris MK; Freedland SJ; Williams SB
Cancer; 2019 Nov; 125(22):4003-4010. PubMed ID: 31390061
[TBL] [Abstract][Full Text] [Related]
16. Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer.
Xiang M; Ma TM; Savjani R; Pollom EL; Karnes RJ; Grogan T; Wong JK; Motterle G; Tosoian JJ; Trock BJ; Klein EA; Stish BJ; Dess RT; Spratt DE; Pilar A; Reddy C; Levin-Epstein R; Wedde TB; Lilleby WA; Fiano R; Merrick GS; Stock RG; Demanes DJ; Moran BJ; Huland H; Tran PT; Martin S; Martinez-Monge R; Krauss DJ; Abu-Isa EI; Alam R; Schwen Z; Pisansky TM; Choo CR; Song DY; Greco S; Deville C; McNutt T; DeWeese TL; Ross AE; Ciezki JP; Boutros PC; Nickols NG; Bhat P; Shabsovich D; Juarez JE; Chong N; Kupelian PA; Rettig MB; Zaorsky NG; Berlin A; Tward JD; Davis BJ; Reiter RE; Steinberg ML; Elashoff D; Horwitz EM; Tendulkar RD; Tilki D; Czernin J; Gafita A; Romero T; Calais J; Kishan AU
JAMA Netw Open; 2021 Dec; 4(12):e2138550. PubMed ID: 34902034
[TBL] [Abstract][Full Text] [Related]
17. Comparison of different lymph node staging schemes in prostate cancer patients with lymph node metastasis.
Jin S; Wang J; Shen Y; Gan H; Xu P; Wei Y; Wei J; Wu J; Wang B; Wang J; Yang C; Zhu Y; Ye D
Int Urol Nephrol; 2020 Jan; 52(1):87-95. PubMed ID: 31552575
[TBL] [Abstract][Full Text] [Related]
18. The prognostic nomogram for PSA-incongruent low-risk prostate cancer treated by radical prostatectomy.
Wang Y; Zhu Y; Fan L; Liu J; Pan J; Xue W
Int Urol Nephrol; 2023 Jun; 55(6):1447-1452. PubMed ID: 37017821
[TBL] [Abstract][Full Text] [Related]
19. A Web-Based Prediction Model for Cancer-Specific Survival of Elderly Patients Undergoing Surgery With Prostate Cancer: A Population-Based Study.
Zhang Z; Zhanghuang C; Wang J; Mi T; Liu J; Tian X; Jin L; He D
Front Public Health; 2022; 10():935521. PubMed ID: 35903379
[TBL] [Abstract][Full Text] [Related]
20. The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer.
Evans CP; Higano CS; Keane T; Andriole G; Saad F; Iversen P; Miller K; Kim CS; Kimura G; Armstrong AJ; Sternberg CN; Loriot Y; de Bono J; Noonberg SB; Mansbach H; Bhattacharya S; Perabo F; Beer TM; Tombal B
Eur Urol; 2016 Oct; 70(4):675-683. PubMed ID: 27006332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]